Drugs.com

FEBRUARY 5, 2025

5, 2025 -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the. WEDNESDAY, Feb.

Drugs 276

Drugs Disease Marketing 276

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. “For diseases like Parkinson’s, it’s more than sufficient,” he explains.

Disease 52

Disease Treatment Therapies Cell Biology 52

Nvidia Developer: Drug Discovery

OCTOBER 30, 2024

The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional.

Drugs 87

Drugs Treatment Disease Research 87

Drug Target Review

DECEMBER 20, 2024

These innovations have started to shift industry perceptions, positioning AI as a transformative tool that could alter how drugs are developed, tested, and brought to market. Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Drug Patent Watch

DECEMBER 12, 2024

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.

Licensing 96

Licensing Licensing Drugs Clinical Trials 96

Conversations in Drug Development Trends

NOVEMBER 5, 2024

In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.

Disease 52

Disease Clinical Trials Therapies Clinical Research 52

BioPharma Drive: Drug Pricing

DECEMBER 10, 2023

While new gene therapies for the blood disease grabbed headlines at ASH, Pfizer presented fresh data for an oral drug meant to build on its marketed therapy Oxbryta.

Therapies 195

Therapies Drugs Disease Marketing 195

Advarra

MARCH 10, 2023

Having a one in four chance of developing sickle cell disease (SCD) is uniquely, and overwhelmingly, familiar to the African American population. Considered a rare disease, research in finding better therapies – and possibly even a cure – for SCD may be competing for funding with conditions impacting broader populations.

Disease 98

Disease Clinical Trials Trials Doctors 98

Cytel

MAY 7, 2024

Here we explore the evolution and impact of market exclusivity policies in the EU and US, highlighting their role in fostering innovation and accessibility in rare disease treatment. Market exclusivity for orphan drugs traces back to the early 1980s in the United States, with the landmark Orphan Drug Act of 1983.

Marketing 59

Marketing Production Drugs Disease 59

PPD

MARCH 11, 2025

While individual rare diseases affect populations that are small in numbers, collectively they impact millions globally, posing significant health and research challenges. Real-world data (RWD) and real-world evidence (RWE) have emerged as transformational tools in addressing these hurdles, advancing rare disease drug development.

Drug Development 52

Drug Development Clinical Trials Disease Trials 52

Fierce BioTech

SEPTEMBER 24, 2024

Unlocking European market access for rare disease therapies The European orphan drug market presents a significant opportunity for biotech firms. Learn more about early access programs (EAPs), and how they are emerging as a critical strategy for successfully launching rare disease therapies in this complex and diverse market.

Marketing 40

Marketing Therapies Disease Drugs 40

PPD

JANUARY 15, 2025

As clinical trials become increasingly complex, particularly in decentralized trials and rare disease studies, sponsors experience increased challenges in site selection, forecasting and resourcing, and patient recruitment and enrollment. Click to enlarge Six AI and machine learning considerations for effective clinical trial management 1.

Clinical Trials 95

Clinical Trials Trials Clinical Research Drug Development 95

SCIENMAG: Medicine & Health

JUNE 9, 2023

Credit: Aston University Aston University and local industry to develop technology to convert organic material into commercially valuable products Sawdust, diseased trees and dried chicken litter among what can be transformed into sustainable bioproducts […] Aston University is to receive £1.8

Marketing 78

Marketing Production Disease Science 78

FDA Law Blog: Drug Discovery

JANUARY 30, 2025

Similarly, the December 2024 draft guidance reiterates prior positions that confirmatory trials should generally be underway at the time the marketing application is submitted but also states that this recommendation becomes a requirement by the time of approval except in limited circumstances. rare disease settings).

FDA 105

FDA Trials Disease Drugs 105

Drug Target Review

DECEMBER 9, 2024

Its applications include studying disease pathology to develop targeted therapeutics, visualising enzymes that can decompose plastics, and engineering solutions to antibiotic resistance, among many others. David Baker is listed as an inventor on many patents, focused on compositions and methods for treating particular diseases.

Engineering 105

Engineering International Drug Development Science 105

Fierce BioTech

FEBRUARY 21, 2024

CNS Market Outlook, 2024 This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment.

Marketing 52

Marketing Science Disease 52

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 69

Clinical Research Disease Research Clinical Trials 69

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2024

In fact, it has a whole page dedicated to “CDRH Innovation,” which states that CDRH “is committed to advancing public health by helping to bring innovative technologies to market.” Manufacturers can expect increased interaction with the review team and prioritized review of the marketing submission.” So what can be done?

Marketing 64

Marketing Clinical Trials FDA Trials 64

Drug Target Review

AUGUST 6, 2024

A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. Oncology also offers high returns and the opportunity to address severe, life-threatening conditions.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Drug Target Review

APRIL 7, 2025

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Monitoring biomarkers can help assess changes in a disease, its level of expression, or the extent of its progression.

Clinical Development 59

Clinical Development Clinical Trials Clinical Pharmacology Trials 59

The Premier Consulting Blog

NOVEMBER 6, 2024

Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. The goal of ICPs is to improve the quality of life for patients suffering from chronic respiratory diseases.

Production 52

Production FDA Compliance Disease 52

Fierce BioTech

AUGUST 26, 2024

Pharma Marketing Trends: Key Takeaways from Digital Pharma East 2024 swheeler Mon, 08/26/2024 - 14:05 Thu, 09/26/2024 - 13:00 Resource Type Webinar Stephanie Butler Promotion Start Tue, 08/27/2024 - 14:15 Promotion End Thu, 02/27/2025 - 14:15 Duration 60 minutes Did you miss the buzz at Digital Pharma East 2024?

Marketing 52

Marketing Disease 52

Drug Target Review

SEPTEMBER 5, 2024

This was very challenging for me and at that moment I decided to get experience from later stage products and therefore took on the role as Global Product Director for late-stage marketed cardiovascular products. In addition, we were a US and Swedish group working together with all that comes with that in form of cultural challenges.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Target Review

MARCH 18, 2024

By enabling a more direct assessment of drug interactions with human tissue, bioprinting can streamline the path from lab to market. They help scientists to better understand organ function and disease mechanisms. These are used for drug testing, disease modelling, and personalised medicine. Tissue and organ models.

Marketing 59

Marketing Animal Testing Engineering Drug Development 59

Fierce BioTech

SEPTEMBER 11, 2023

Aligning cross-functional teams across the organization to ensure medical, marketing, and market access are all in lock-step is even more crucial when launching a therapy into a rare disease market. Listing Image HerspiegelConsulting_LogoListingNew_10262023.png On Demand Start Date Thu, 10/26/2023 - 11:00

Production 52

Production Disease FDA Approval Therapies 52

Drug Patent Watch

DECEMBER 9, 2024

High-Throughput Screening: Modern Technology Meets Natural Products Advanced technologies now allow researchers to rapidly test thousands of natural compounds against specific disease targets. This approach has led to the discovery of numerous potential drug candidates.

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Therapies Pharmaceuticals Clinical Trials 49

DrugBank

AUGUST 9, 2024

  The average cost of bringing a new drug to market is about $2.6 Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  The market for cardiovascular drugs, valued at 155.6 trillion by 2028.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

Fierce BioTech

OCTOBER 9, 2023

Join us for a webinar on Tuesday, Novermber 14th, featuring Sara Mallatt Stahl, Director of Healthcare Research at AlphaSense.

Marketing 52

Marketing Science Treatment Disease 52

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The treatment often initially provides good symptom relief and those affected by the disease can live a largely normal life.

Disease 52

Disease Drugs Treatment Drug Development 52

Fierce BioTech

JANUARY 9, 2024

This webinar provides a roadmap for organizations seeking to marry scientific excellence with market access acumen, driving transformative change for the benefit of patients. Listing Image QuartzListingLogo_250x190_clarivate.png Listing Introduction From R&D Promise to In-market Wins. Click here to login.

Marketing 52

Marketing Drugs Science Disease 52

Chemical Biology and Drug Design

SEPTEMBER 4, 2023

Alzheimer's disease (AD) is a chronic age-related neurodegenerative brain disorder characterized by the impairment of memory accompanied by worsening of thinking ability of an individual. Due to the complex pathophysiology of AD, no specific treatment is available in the market, and treatment are only limited to the symptomatic relief.

Treatment 100

Treatment Disease Marketing Drugs 100

ProRelix Research

JULY 6, 2023

Biosimilar clinical trials and study designs’ Considerations The rising prevalence and large market share of biological products emphasize their importance as treatment options for several cancers and autoimmune diseases.

Clinical Trials 105

Clinical Trials Biosimilars Trials Treatment 105

Drug Discovery Today

APRIL 7, 2020

New arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system. First in the market, this unique service complements the Company’s T cell screening service

Disease 100

Disease Marketing 100

Drug Target Review

JULY 4, 2023

The drivers behind the demand for ADCs Providing more targeted therapeutic options in the oncology space has underpinned the rapid growth of the ADC market; between 2016 to 2020, the US ADC market grew by 45 percent to a value of nearly $1.5 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Sygnature Discovery

FEBRUARY 12, 2025

He will also spearhead the development and implementation of a dynamic go-to-market strategy, designed to leverage the group’s strengths and enhance customer relationships through an even more responsive and scientifically driven commercial organization.

Disease 52

Disease Science Marketing Drugs 52